{
    "json": {},
    "html": "<table><thead><tr><th></th><th colspan='5'>PIRS&nbsp;&nbsp;&nbsp;Data Collection Tool: MER 2.0 Indicator - TX_ML (Based on MER 2 0 Indicator&nbsp;&nbsp;&nbsp;Reference Guide September 2023 v2.7)</th></tr></thead><tbody><tr><td>Indicator&nbsp;&nbsp;&nbsp;Code</td><td colspan='2'>Indicator&nbsp;&nbsp;&nbsp;Name &amp; Disaggregation's</td><td>Female</td><td>Male</td><td>Total</td></tr><tr><td rowspan='15'>TX_RTT</td><td colspan='2'>Number of ART patients who experienced IIT&nbsp;&nbsp;&nbsp;during any previous reporting period, who successfully restarted ARVs within&nbsp;&nbsp;&nbsp;the reporting period and remained on treatment until the end of the reporting&nbsp;&nbsp;&nbsp;period. </td><td> </td><td> </td><td> </td></tr><tr><td rowspan='15'>Numerator: Number of ART patients who experienced IIT during any previous&nbsp;&nbsp;&nbsp;reporting period, who successfully restarted ARVs within the reporting period&nbsp;&nbsp;&nbsp;and remained on treatment until the end of the reporting period by  Age/Sex: CD4 &lt;200</td><td>&lt; 1 year</td><td>#TX.2a#</td><td>#TX.2b#</td><td></td></tr><tr><td>1\u00AD4 years</td><td>#TX.3a#</td><td>#TX.3b#</td><td></td></tr><tr><td>5\u00AD 9 years</td><td>#TX.4a#</td><td>#TX.4b#</td><td></td></tr><tr><td>10\u00AD14 years</td><td>#TX.5a#</td><td>#TX.5b#</td><td></td></tr><tr><td>15\u00AD19 years</td><td>#TX.6a#</td><td>#TX.6b#</td><td></td></tr><tr><td>20\u00AD24 years</td><td>#TX.7a#</td><td>#TX.7b#</td><td></td></tr><tr><td>25\u00AD29 years</td><td>#TX.8a#</td><td>#TX.8b#</td><td></td></tr><tr><td>30\u00AD34 years</td><td>#TX.9a#</td><td>#TX.9b#</td><td></td></tr><tr><td>35\u00AD39 years</td><td>#TX.10a#</td><td>#TX.10b#</td><td></td></tr><tr><td>40-44 years</td><td>#TX.11a#</td><td>#TX.11b#</td><td></td></tr><tr><td>45\u00AD49 years</td><td>#TX.12a#</td><td>#TX.12b#</td><td></td></tr><tr><td>50-54 years</td><td>#TX.13a#</td><td>#TX.13b#</td><td></td></tr><tr><td>55-59 years</td><td>#TX.14a#</td><td>#TX.14b#</td><td></td></tr><tr><td>60-64years</td><td>#TX.15a#</td><td>#TX.15b#</td><td></td></tr><tr><td> </td><td>65+ years</td><td>#TX.16a#</td><td>#TX.16b#</td><td></td></tr><tr><td> </td><td rowspan='15'>Numerator: Number&nbsp;&nbsp;&nbsp;of ART patients who experienced IIT during any previous reporting period, who&nbsp;&nbsp;&nbsp;successfully restarted ARVs within the reporting period and remained on&nbsp;&nbsp;&nbsp;treatment until the end of the reporting period by  Age/Sex: CD4â‰¥200</td><td>&lt; 1 year</td><td>#TX.2c#</td><td>#TX.2d#</td><td></td></tr><tr><td> </td><td>1\u00AD4 years</td><td>#TX.3c#</td><td>#TX.3d#</td><td></td></tr><tr><td> </td><td>5\u00AD 9 years</td><td>#TX.4c#</td><td>#TX.4d#</td><td></td></tr><tr><td> </td><td>10\u00AD14 years</td><td>#TX.5c#</td><td>#TX.5d#</td><td></td></tr><tr><td> </td><td>15\u00AD19 years</td><td>#TX.6c#</td><td>#TX.6d#</td><td></td></tr><tr><td> </td><td>20\u00AD24 years</td><td>#TX.7c#</td><td>#TX.7d#</td><td></td></tr><tr><td> </td><td>25\u00AD29 years</td><td>#TX.8c#</td><td>#TX.8d#</td><td></td></tr><tr><td> </td><td>30\u00AD34 years</td><td>#TX.9c#</td><td>#TX.9d#</td><td></td></tr><tr><td> </td><td>35\u00AD39 years</td><td>#TX.10c#</td><td>#TX.10d#</td><td></td></tr><tr><td> </td><td>40-44 years</td><td>#TX.11c#</td><td>#TX.11d#</td><td></td></tr><tr><td> </td><td>45\u00AD49 years</td><td>#TX.12c#</td><td>#TX.12d#</td><td></td></tr><tr><td> </td><td>50-54 years</td><td>#TX.13c#</td><td>#TX.13d#</td><td></td></tr><tr><td> </td><td>55-59 years</td><td>#TX.14c#</td><td>#TX.14d#</td><td></td></tr><tr><td> </td><td>60-64years</td><td>#TX.15c#</td><td>#TX.15d#</td><td></td></tr><tr><td> </td><td>65+ years</td><td>#TX.16c#</td><td>#TX.16d#</td><td></td></tr><tr><td> </td><td rowspan='15'>Numerator: Number&nbsp;&nbsp;&nbsp;of ART patients who experienced IIT during any previous reporting period, who&nbsp;&nbsp;&nbsp;successfully restarted ARVs within the reporting period and remained on&nbsp;&nbsp;&nbsp;treatment until the end of the reporting period by  Age/Sex: Unknown&nbsp;&nbsp;&nbsp;CD4</td><td>&lt; 1 year</td><td>#TX.2e#</td><td>#TX.2f#</td><td></td></tr><tr><td> </td><td>1\u00AD4 years</td><td>#TX.3e#</td><td>#TX.3f#</td><td></td></tr><tr><td> </td><td>5\u00AD 9 years</td><td>#TX.4e#</td><td>#TX.4f#</td><td></td></tr><tr><td> </td><td>10\u00AD14 years</td><td>#TX.5e#</td><td>#TX.5f#</td><td></td></tr><tr><td> </td><td>15\u00AD19 years</td><td>#TX.6e#</td><td>#TX.6f#</td><td></td></tr><tr><td> </td><td>20\u00AD24 years</td><td>#TX.7e#</td><td>#TX.7f#</td><td></td></tr><tr><td> </td><td>25\u00AD29 years</td><td>#TX.8e#</td><td>#TX.8f#</td><td></td></tr><tr><td> </td><td>30\u00AD34 years</td><td>#TX.9e#</td><td>#TX.9f#</td><td></td></tr><tr><td> </td><td>35\u00AD39 years</td><td>#TX.10e#</td><td>#TX.10f#</td><td></td></tr><tr><td> </td><td>40-44 years</td><td>#TX.11e#</td><td>#TX.11f#</td><td></td></tr><tr><td> </td><td>45\u00AD49 years</td><td>#TX.12e#</td><td>#TX.12f#</td><td></td></tr><tr><td> </td><td>50-54 years</td><td>#TX.13e#</td><td>#TX.13f#</td><td></td></tr><tr><td> </td><td>55-59 years</td><td>#TX.14e#</td><td>#TX.14f#</td><td></td></tr><tr><td> </td><td>60-64years</td><td>#TX.15e#</td><td>#TX.15f#</td><td></td></tr><tr><td> </td><td>65+ years</td><td>#TX.16e#</td><td>#TX.16f#</td><td></td></tr><tr><td> </td><td rowspan='15'>Numerator: Number&nbsp;&nbsp;&nbsp;of ART patients who experienced IIT during any previous reporting period, who&nbsp;&nbsp;&nbsp;successfully restarted ARVs within the reporting period and remained on&nbsp;&nbsp;&nbsp;treatment until the end of the reporting period by  Age/Sex: Not&nbsp;&nbsp;&nbsp;Eligible for CD4</td><td>&lt; 1 year</td><td>#TX.2g#</td><td>#TX.2h#</td><td></td></tr><tr><td> </td><td>1\u00AD4 years</td><td>#TX.3g#</td><td>#TX.3h#</td><td></td></tr><tr><td> </td><td>5\u00AD 9 years</td><td>#TX.4g#</td><td>#TX.4h#</td><td></td></tr><tr><td> </td><td>10\u00AD14 years</td><td>#TX.5g#</td><td>#TX.5h#</td><td></td></tr><tr><td> </td><td>15\u00AD19 years</td><td>#TX.6g#</td><td>#TX.6h#</td><td></td></tr><tr><td> </td><td>20\u00AD24 years</td><td>#TX.7g#</td><td>#TX.7h#</td><td></td></tr><tr><td> </td><td>25\u00AD29 years</td><td>#TX.8g#</td><td>#TX.8h#</td><td></td></tr><tr><td> </td><td>30\u00AD34 years</td><td>#TX.9g#</td><td>#TX.9h#</td><td></td></tr><tr><td> </td><td>35\u00AD39 years</td><td>#TX.10g#</td><td>#TX.10h#</td><td></td></tr><tr><td> </td><td>40-44 years</td><td>#TX.11g#</td><td>#TX.11h#</td><td></td></tr><tr><td> </td><td>45\u00AD49 years</td><td>#TX.12g#</td><td>#TX.12h#</td><td></td></tr><tr><td> </td><td>50-54 years</td><td>#TX.13g#</td><td>#TX.13h#</td><td></td></tr><tr><td> </td><td>55-59 years</td><td>#TX.14g#</td><td>#TX.14h#</td><td></td></tr><tr><td> </td><td>60-64years</td><td>#TX.15g#</td><td>#TX.15h#</td><td></td></tr><tr><td> </td><td>65+ years</td><td>#TX.16g#</td><td>#TX.16h#</td><td></td></tr><tr><td> </td><td rowspan='4'>Number of ART patients who experienced IIT during any previous&nbsp;&nbsp;&nbsp;reporting period, who successfully restarted ARVs within the reporting period&nbsp;&nbsp;&nbsp;and remained on treatment until the end of the reporting period disaggregated&nbsp;&nbsp;&nbsp;by Key  Population<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KP should be counted in only one KP group to avoid&nbsp;&nbsp;&nbsp;double-counting.)</td><td>Men&nbsp;&nbsp;&nbsp;who have Sex with men (MSM)</td><td> </td><td> </td><td>#TX.PWIDS#</td></tr><tr><td> </td><td>Transgender&nbsp;&nbsp;&nbsp;people (TG)</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Female&nbsp;&nbsp;&nbsp;Sex Workers (FSW)</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>People&nbsp;&nbsp;&nbsp;in prisons and other enclosed settings (Incarcerated Population) </td><td> </td><td> </td><td>#TX.PIPS#</td></tr><tr><td> </td><td rowspan='3'>Duration of treatment interruption before&nbsp;&nbsp;&nbsp;returning to treatment [Required]</td><td>Experienced&nbsp;&nbsp;&nbsp;treatment interruption of &lt;3 months before returning to treatment </td><td>#TX.2x#</td><td>#TX.2y#</td><td></td></tr><tr><td> </td><td>Experienced&nbsp;&nbsp;&nbsp;treatment interruption of 3-5 months before returning to treatment </td><td>#TX.3x#</td><td>#TX.3y#</td><td></td></tr><tr><td> </td><td>Experienced&nbsp;&nbsp;&nbsp;treatment interruption of 6+ months before returning to treatment </td><td>#TX.4x#</td><td>#TX.4y#</td><td></td></tr></tbody></table>"}